Combination therapy significantly enhances outcomes in advanced hepatocellular carcinoma

The integration of transarterial chemoembolization (TACE) with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) notably improves the objective response rate (RR = 1.81) and disease control rate (RR = 1.32) compared to TKIs and ICIs alone. Additionally, overall survival and progression-free survival are significantly prolonged, with hazard ratios of 0.55 and 0.73, respectively. While higher rates of pain and nausea/vomiting were observed, the therapy maintains an acceptable safety profile overall.